21173-Breast Cancer-NA-564

Breast Cancer

SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

  • Details

ClinicalTrials.gov ID: NCT04964934
Diagnosis Type: NA
USOR Number:

  • Address

8820 Huron St
Thornton, CO 80260
P: (303) 386-7622

Search by practice name, trial titles, indicators and specific disease types.